New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:15 EDTSI, THLDThreshold Pharmaceuticals acquires [18F]HX4 from Siemens Healthcare
Threshold Pharmaceuticals (THLD) announced a global agreement with Siemens Healthcare (SI) to acquire its investigational agent [18F]HX4, a radiolabeled hypoxia Positron Emission Tomography, or PET, tracer. [18F]HX4 could potentially be used as a companion diagnostic to hypoxia-targeted therapeutics based on Threshold's drug discovery platform. Threshold initially intends to develop [18F]HX4 to determine a patient's tumor hypoxia profile, which may identify patients who will best respond to Threshold's hypoxia-targeted therapeutics. Under the terms of the agreement, Siemens will transfer ownership and existing preclinical, clinical and manufacturing data related to [18F]HX4 to Threshold.
News For THLD;SI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 7, 2014
16:48 EDTTHLDThreshold Pharmaceuticals announces data from TH-302 study
Threshold Pharmaceuticals announced new preliminary data from the Phase 2 component of an ongoing company-sponsored Phase 1/2 trial of TH-302, the company's lead investigational anticancer drug, in combination with the proteasome inhibitor bortezomib, Velcade, and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma. The median number of prior therapies was 8. The recommended phase 2 dose of TH-302 was determined to be 340 mg/m2 and no dose limiting toxicities were observed at this dose level. Partial responses were observed in 2 of 7 evaluable patients overall and 2 of 4 evaluable patients at the recommended phase 2 dose of TH-302. These data are being presented today at the 56th ASH Annual Meeting and Exposition in San Francisco, California.
14:10 EDTTHLDAmerican Society of Hematology to hold a meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use